AU2005267331A1 - Amido compounds and their use as pharmaceuticals - Google Patents

Amido compounds and their use as pharmaceuticals Download PDF

Info

Publication number
AU2005267331A1
AU2005267331A1 AU2005267331A AU2005267331A AU2005267331A1 AU 2005267331 A1 AU2005267331 A1 AU 2005267331A1 AU 2005267331 A AU2005267331 A AU 2005267331A AU 2005267331 A AU2005267331 A AU 2005267331A AU 2005267331 A1 AU2005267331 A1 AU 2005267331A1
Authority
AU
Australia
Prior art keywords
cycloalkyl
heteroaryl
heterocycloalkyl
aryl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005267331A
Other languages
English (en)
Inventor
Yun-Long Li
Brian Metcalf
Meizhong Xu
Wenqing Yao
Colin Zhang
Jincong Zhuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2005267331A1 publication Critical patent/AU2005267331A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005267331A 2004-06-24 2005-06-23 Amido compounds and their use as pharmaceuticals Abandoned AU2005267331A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58247804P 2004-06-24 2004-06-24
US60/582,478 2004-06-24

Publications (1)

Publication Number Publication Date
AU2005267331A1 true AU2005267331A1 (en) 2006-02-02

Family

ID=35786518

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005267331A Abandoned AU2005267331A1 (en) 2004-06-24 2005-06-23 Amido compounds and their use as pharmaceuticals

Country Status (9)

Country Link
US (1) US20050288317A1 (enExample)
EP (1) EP1758882A4 (enExample)
JP (1) JP2008504274A (enExample)
CN (1) CN101001850A (enExample)
AU (1) AU2005267331A1 (enExample)
BR (1) BRPI0512630A (enExample)
CA (1) CA2569507A1 (enExample)
MX (1) MXPA06014573A (enExample)
WO (1) WO2006012173A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2006012227A2 (en) * 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006002361A2 (en) * 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
WO2006002349A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
KR20070050076A (ko) * 2004-08-10 2007-05-14 인사이트 산 디에고 인코포레이티드 아미도 화합물 및 약제로서의 이의 용도
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
KR101368228B1 (ko) * 2004-11-10 2014-02-27 인사이트 코포레이션 락탐 화합물 및 약제로서의 이의 용도
MX2007005820A (es) * 2004-11-18 2007-07-18 Incyte Corp Inhibidores de deshidrogenasa esteroide hidroxilo 11-beta tipo 1 y metodos de uso de los mismos.
KR101496190B1 (ko) 2005-01-05 2015-02-26 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
KR101302627B1 (ko) 2005-01-05 2013-09-10 아비에 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
CN101133026B (zh) * 2005-03-03 2011-07-06 霍夫曼-拉罗奇有限公司 作为治疗Ⅱ型糖尿病用的11β-羟基类固醇脱氢酶抑制剂的1-磺酰基-哌啶-3-羧酸酰胺衍生物
WO2006105127A2 (en) * 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
EP2527337A1 (en) * 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
EP1931652A2 (en) * 2005-09-21 2008-06-18 Incyte Corporation Amido compounds and their use as pharmaceuticals
AU2006322060A1 (en) * 2005-12-05 2007-06-14 Incyte Corporation Lactam compounds and methods of using the same
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
KR20080091503A (ko) * 2006-01-31 2008-10-13 인사이트 코포레이션 아미도 화합물 및 약제로서의 이의 용도
US7632838B2 (en) 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
US20070213311A1 (en) * 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070293529A1 (en) * 2006-05-01 2007-12-20 Yun-Long Li Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007137066A2 (en) * 2006-05-17 2007-11-29 Incyte Corporation HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
CN101605456A (zh) * 2006-12-20 2009-12-16 詹森药业有限公司 用甲硅烷基试剂由哌啶酮合成不饱和哌啶
CN101641348B (zh) * 2007-03-30 2014-09-10 霍夫曼-拉罗奇有限公司 咪唑烷酮衍生物
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
CN103772299A (zh) 2007-08-13 2014-05-07 霍夫曼-拉罗奇有限公司 新型哌嗪酰胺衍生物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
ES2367341T3 (es) * 2008-02-12 2011-11-02 F. Hoffmann-La Roche Ag Derivados de piperidina-sulfonamida.
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
CN102753556B (zh) 2009-10-14 2015-05-13 泽农医药公司 螺-羟吲哚化合物的合成方法
NZ601667A (en) 2010-02-26 2014-10-31 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
KR102351054B1 (ko) * 2019-11-11 2022-01-14 엠비디 주식회사 신규한 퀴놀린 화합물 및 이의 용도
US12612384B2 (en) 2021-05-07 2026-04-28 MBD Co., Ltd. Heterocyclic CYP4A inhibitor compounds and compositions thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439606A (en) * 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2705343B1 (fr) * 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
FR2724656B1 (fr) * 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
CN1329382C (zh) * 2001-05-11 2007-08-01 比奥维特罗姆股份公司 治疗肥胖、ⅱ型糖尿病和cns－疾病的芳基磺酰胺化合物
WO2003000657A1 (en) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US6547958B1 (en) * 2001-07-13 2003-04-15 Chevron U.S.A. Inc. Hydrocarbon conversion using zeolite SSZ-59
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
GB0213715D0 (en) * 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
EP1553098A1 (en) * 2002-10-18 2005-07-13 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2006002361A2 (en) * 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
WO2006012227A2 (en) * 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006002349A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
EA200700117A1 (ru) * 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
KR20070050076A (ko) * 2004-08-10 2007-05-14 인사이트 산 디에고 인코포레이티드 아미도 화합물 및 약제로서의 이의 용도
KR101368228B1 (ko) * 2004-11-10 2014-02-27 인사이트 코포레이션 락탐 화합물 및 약제로서의 이의 용도
MX2007005820A (es) * 2004-11-18 2007-07-18 Incyte Corp Inhibidores de deshidrogenasa esteroide hidroxilo 11-beta tipo 1 y metodos de uso de los mismos.
KR101302627B1 (ko) * 2005-01-05 2013-09-10 아비에 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제
CN101133026B (zh) * 2005-03-03 2011-07-06 霍夫曼-拉罗奇有限公司 作为治疗Ⅱ型糖尿病用的11β-羟基类固醇脱氢酶抑制剂的1-磺酰基-哌啶-3-羧酸酰胺衍生物
EP1931652A2 (en) * 2005-09-21 2008-06-18 Incyte Corporation Amido compounds and their use as pharmaceuticals
AU2006322060A1 (en) * 2005-12-05 2007-06-14 Incyte Corporation Lactam compounds and methods of using the same
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
KR20080091503A (ko) * 2006-01-31 2008-10-13 인사이트 코포레이션 아미도 화합물 및 약제로서의 이의 용도
US20070213311A1 (en) * 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070293529A1 (en) * 2006-05-01 2007-12-20 Yun-Long Li Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
WO2007137066A2 (en) * 2006-05-17 2007-11-29 Incyte Corporation HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME

Also Published As

Publication number Publication date
MXPA06014573A (es) 2007-03-12
EP1758882A4 (en) 2008-01-23
CN101001850A (zh) 2007-07-18
BRPI0512630A (pt) 2008-03-25
EP1758882A1 (en) 2007-03-07
CA2569507A1 (en) 2006-02-02
JP2008504274A (ja) 2008-02-14
US20050288317A1 (en) 2005-12-29
WO2006012173A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
US20050288317A1 (en) Amido compounds and their use as pharmaceuticals
US8071624B2 (en) N-substituted piperidines and their use as pharmaceuticals
US20060009491A1 (en) Amido compounds and their use as pharmaceuticals
US7838544B2 (en) Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same
US20070293529A1 (en) Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
US20060009471A1 (en) Amido compounds and their use as pharmaceuticals
US20070066584A1 (en) Amido compounds and their use as pharmaceuticals
US20060122210A1 (en) Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same
WO2007089683A1 (en) Amido compounds and their use as pharmaceuticals
US20100256114A1 (en) Amido Compounds And Their Use As Pharmaceuticals
KR20070031954A (ko) 아미도 화합물 및 약제로서의 이의 용도

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR BY DELETING CO-INVENTOR LI, YANLONG AND INCLUDING CO-INVENTOR LI, YUN-LONG

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application